What is Modulus Therapeutics?
Modulus Therapeutics is at the forefront of mainstreaming cell therapies for autoimmune diseases, employing innovative rapid prototyping and generative design strategies. The company is dedicated to overcoming the limitations of existing CAR-T treatments by developing off-the-shelf CAR-NK therapies, aiming to enhance safety and accessibility for patients. Their proprietary platform enables the creation of custom CARs and switch receptors, boosting the efficacy of immune cell therapies while mitigating the complex preparation typically required. Modulus Therapeutics primarily serves autoimmune patients seeking advanced and more readily available cell therapy solutions.
How much funding has Modulus Therapeutics raised?
Modulus Therapeutics has raised a total of $3.5M across 1 funding round:
Angel/Seed
$3.5M
Angel/Seed (2021): $3.5M with participation from Ai2, Madrona Venture Group, and KdT Ventures
Key Investors in Modulus Therapeutics
Ai2
Ai2 is focused on preventing medical device infections with their peptide coatings, offering a non-cytotoxic and cost-effective alternative to existing solutions. Their technology is highly efficacious and aims to create truly infection-free medical devices.
Madrona Venture Group
Madrona Venture Group is a venture capital firm established in 1995, with investment interests spanning consumer internet, commercial software, and services.
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science, particularly in medicine, chemicals, and materials. They focus on transformative technologies and often lead pre-seed and seed rounds.
What's next for Modulus Therapeutics?
The substantial enterprise-level funding positions Modulus Therapeutics for significant expansion and accelerated development of its innovative cell therapy platform. This capital injection is expected to fuel advancements in their generative design and rapid prototyping capabilities, crucial for scaling their off-the-shelf CAR-NK therapies. The strategic investment signals a strong market appetite for their approach to making cell therapies more accessible and safer for autoimmune disease patients. Future growth will likely involve further clinical validation, strategic partnerships, and broader market penetration, solidifying their role in the evolving landscape of immunotherapy.
See full Modulus Therapeutics company page
